- Otoukesh B, Boddouhi B, Moghtadaei M, Kaghazian P, Kaghazian M. Novel molecular insights and
new therapeutic strategies in osteosarcoma. Cancer Cell Int. 2018;18:158.
- Kumar R, Kumar M, Malhotra K, Patel S. Primary Osteosarcoma in the Elderly Revisited: Current
Concepts in Diagnosis and Treatment. Curr Oncol Rep. 2018;20(2):13.
- Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS, et al. Treatment pathway of bone
sarcoma in children, adolescents, and young adults. Cancer. 2017;123(12):2206-18.
- Serra M, Scotlandi K, Sollazzo M, Sarti M, Maurici D, Benini S, et al. Value of immunohistochemical
detection of noncollagenous proteins of bone for the diagnosis of bone tumours. Int J Oncol.
1996;9(2):257-61.
- Schulz A, Jundt G, Berghauser KH, Gehron-Robey P, Termine JD. Immunohistochemical study of
osteonectin in various types of osteosarcoma. Am J Pathol. 1988;132(2):233-8.
- Wuisman P, Roessner A, Bosse A, Ueda Y, Winkelmann W, Enneking WF. Osteonectin in osteosarcomas:
a marker for differential diagnosis and/or prognosis? Ann Oncol. 1992;3 Suppl 2:S33-5.
- Kashima TG, Dongre A, Oppermann U, Athanasou NA. Dentine matrix protein 1 (DMP-1) is a marker
of bone-forming tumours. Virchows Arch. 2013;462(5):583-91.
- Inoue T, Hagiyama M, Enoki E, Sakurai MA, Tan A, Wakayama T, et al. Cell adhesion molecule 1 is a
new osteoblastic cell adhesion molecule and a diagnostic marker for osteosarcoma. Life Sci.
2013;92(1):91-9.
- Gomez-Brouchet A, Mourcin F, Gourraud PA, Bouvier C, De Pinieux G, Le Guelec S, et al. Galectin-1 is
a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma.
Hum Pathol. 2010;41(9):1220-30.
- Hua Y, Jia X, Sun M, Zheng L, Yin L, Zhang L, et al. Plasma membrane proteomic analysis of human
osteosarcoma and osteoblastic cells: revealing NDRG1 as a marker for osteosarcoma. Tumour Biol.
2011;32(5):1013-21.
- Conner JR, Hornick JL. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue
tumours. Histopathology. 2013;63(1):36-49.
- Davis JL, Horvai AE. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but
may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.
Histopathology. 2016;69(1):84-90.
- Lange A, Mills RE, Lange CJ, Stewart M, Devine SE, Corbett AH. Classical nuclear localization signals:
definition, function, and interaction with importin alpha. J Biol Chem. 2007;282(8):5101-5.
- Moroianu J, Hijikata M, Blobel G, Radu A. Mammalian karyopherin alpha 1 beta and alpha 2 beta
heterodimers: alpha 1 or alpha 2 subunit binds nuclear localization signal and beta subunit interacts
with peptide repeat-containing nucleoporins. Proc Natl Acad Sci U S A. 1995;92(14):6532-6.
- Alshareeda AT, Negm OH, Green AR, Nolan CC, Tighe P, Albarakati N, et al. KPNA2 is a nuclear export
protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer.
Br J Cancer. 2015;112(12):1929-37.
- Christiansen A, Dyrskjot L. The functional role of the novel biomarker karyopherin alpha 2 (KPNA2)
in cancer. Cancer Lett. 2013;331(1):18-23.
- Altan B, Yokobori T, Mochiki E, Ohno T, Ogata K, Ogawa A, et al. Nuclear karyopherin-alpha2
expression in primary lesions and metastatic lymph nodes was associated with poor prognosis and
progression in gastric cancer. Carcinogenesis. 2013;34(10):2314-21.
- Zhang Y, Zhang M, Yu F, Lu S, Sun H, Tang H, et al. Karyopherin alpha 2 is a novel prognostic marker
and a potential therapeutic target for colon cancer. J Exp Clin Cancer Res. 2015;34:145.
- Sakai M, Sohda M, Miyazaki T, Suzuki S, Sano A, Tanaka N, et al. Significance of karyopherin-{alpha}
2 (KPNA2) expression in esophageal squamous cell carcinoma. Anticancer Res. 2010;30(3):851-6.
- Huang L, Zhou Y, Cao XP, Lin JX, Zhang L, Huang ST, et al. KPNA2 is a potential diagnostic serum
biomarker for epithelial ovarian cancer and correlates with poor prognosis. Tumour Biol. 2017;
39(6):1010428317706289.
- Jiang P, Tang Y, He L, Tang H, Liang M, Mai C, et al. Aberrant expression of nuclear KPNA2 is correlated
with early recurrence and poor prognosis in patients with small hepatocellular carcinoma after
hepatectomy. Med Oncol. 2014;31(8):131.
- Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, et al. Adjuvant chemotherapy of
high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma
Study. Clin Orthop Relat Res. 1991(270):8-14.
- Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a
randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin,
doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004-11.
- Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative
Pathway to Success. J Clin Oncol. 2015;33(27):3029-35.
- Italiano A, Mir O, Cioffi A, Palmerini E, Piperno-Neumann S, Perrin C, et al. Advanced
chondrosarcomas: role of chemotherapy and survival. Ann Oncol. 2013;24(11):2916-22.
- Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. Cancer. 2006;106(12):
2682-91.
- Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y, et al. Dedifferentiated
chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer.
2007;43(14):2060-5.
- Paulino AC, Fowler BZ. Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr
Hematol Oncol. 2005;22(2):89-101.
- DuBois SG, Krailo MD, Gebhardt MC, Donaldson SS, Marcus KJ, Dormans J, et al. Comparative
evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's
Oncology Group. Cancer. 2015;121(3):467-75.
- Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and
etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of
bone. N Engl J Med. 2003;348(8):694-701.
- Dankof A, Fritzsche FR, Dahl E, Pahl S, Wild P, Dietel M, et al. KPNA2 protein expression in invasive
breast carcinoma and matched peritumoral ductal carcinoma in situ. Virchows Arch. 2007;451(5):
877-81.